Table 2.
Chemotherapies at study entry independent from therapy lines according to genomic BRCA (gBRCA) mutation and hormone receptor (HR) status (N = 471)
| Chemotherapy | gBRCA mutation status | Hormone receptor status | ||
|---|---|---|---|---|
| Mutation (N = 23) | Wildtype (N = 448) | Positive (N = 388) | Negative (N = 76) | |
| Anthracyline taxane combination | 2 (8.7) | 32 (7.1) | 32 (8.2) | 1 (1.3) |
| Anthracycline monotherapy | 1 (4.3) | 56 (12.5) | 56 (14.4) | 0 (0.0) |
| Taxane monotherapy | 6 (26.1) | 100 (22.3) | 88 (22.7) | 16 (21.1) |
| Bevacizumab treatments | 4 (17.4) | 106 (23.7) | 89 (22.9) | 20 (26.3) |
| Platinum-based therapy | 8 (34.8) | 47 (10.5) | 30 (7.7) | 24 (31.6) |
| Eribulin | 1 (4.3) | 31 (6.9) | 20 (5.2) | 11 (14.5) |
| Capecitabine monotherapy | 1 (4.3) | 45 (10.0) | 43 (11.1) | 3 (3.9) |
| Capecitabine taxane combination | 0 (0.0) | 7 (1.6) | 7 (1.8) | 0 (0.0) |
| Vinorelbine monotherapy | 0 (0.0) | 11 (2.5) | 11 (2.8) | 0 (0.0) |
| Other | 0 (0.0) | 13 (2.9) | 12 (3.1) | 1 (1.3) |
Treatment patterns for number of cycles per line, schedules, durations and reason for discontinuation are not available. Data is presented as N (%)